

(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021.

The audited financial statements of the Group for the year ended 31 December 2021 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2021.

2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2021 were no subject to any qualification.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect on the current quarter results.

5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

6. DIVIDENDS PAID

There was no dividend paid during the current quarter under review.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

7. TRADE AND OTHER RECEIVABLES

	As at 30-Jun-22	As at 31-Dec-21
	RM ('000)	RM ('000)
Trade Receivables		
Third parties	35,083	37,965
Allowance for impairment loss	(3,790)	(3,790)
	31,293	34,175
Other Receivables		
Third and Related parties	8,143	12,499
Allowance for impairment loss	-	-
	8,143	12,499
Deposits and Prepayments	2,167	2,510
	41,603	49,184

a) Trade Receivables

The Group's normal trade credit term ranges from 30 to 90 days (2021: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	As at 30-Jun-22 RM ('000)	As at 31-Dec-21 RM ('000)
Not past due	21,642	16,887
Past due:		
- Less than 30 days	2,640	12,996
- 31 to 60 days	2,146	3,747
- 61 to 90 days	552	775
- More than 90 days	8,103	3,560
	35,083	37,965
Less: Loss allowance		
 Collectively impaired 	(180)	(180)
- Individually impaired	(3,610)	(3,610)
Trade Receivable net	31,293	34,175



(Company No : 200301016113 (618533-M))
(Incorporated in Malaysia)
SECOND QUARTER REPORT ENDED 30 JUNE 2022

SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

8. SEGMENTAL INFORMATION

Healthcare: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which is for home and center-based treatments, serving both the domestic and export markets. This renal dialysis business was disposed of on 3 May 2021.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for the current quarter are as follow:

Revenue	Individual Quarter Ended		Cumulative Q	uarter Ended
	30-Jun-22	30-Jun-21	30-Jun-22	30-Jun-21
Segment	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	22,624	20,068	40,919	33,053
Corporate	240	177	480	586
Elimination	(963)	(182)	(1,203)	(620)
Total	21,901	20,063	40,196	33,019
DDT//I DT\ magnil				
PBT/(LBT) result Segment	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	434	8,497	1,374	7,326
Corporate	(165)	(769)	(195)	(889)
Elimination	_	-	-	-
Total	269	7,728	1,179	6,437

9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.



(Company No : 200301016113 (618533-M))
(Incorporated in Malaysia)
SECOND OUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

10. SIGNIFICANT EVENTS

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

11. CHANGES IN COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the financial period ended 30 June 2022. Subsequent to the financial period the following are the changes:

- i) On 5 July 2022, Adventa Berhad incorporated Adventa Healthcare Pte. Ltd. with 100 equity interest comprising 100 ordinary shares of SGD1 each for a total paid up capital of SGD100. The company became a subsidiary of the Group since the date of incorporation.
- ii) On 12 July 2022, Adventa Berhad incorporated Adventa Digital Healthcare Sdn Bhd with 100% equity interest comprising 2 ordinary shares of RM1 each for a total paid up capital of RM2. The company became a subsidiary of the Group since the date of incorporation.
- iii) On 29 July 2022, Adventa Berhad incorporated PT Adventa Biotech International with 100% equity interest comprising 11,000 ordinary shares of IDR1,000,000 each for a total paid up capital of IDR11,000,000,000. The company became a subsidiary of the Group since the date of incorporation
- iv) On 26 August 2022, Adventa Berhad incorporated Nextech Med Pte. Ltd. with 49% equity interest comprising 100 ordinary shares of SGD1 each for a total paid up capital of SGD100. The company became an associate company of the Group since the date of incorporation.

12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

13. CAPITAL COMMITMENTS

There were no material capital commitments at the financial period ended 30 June 2022.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

14. PERFORMANCE REVIEW

	Individual Quarter Ended 2Q 2022 RM ('000)	Individual Quarter Ended 2Q 2021 RM ('000)	Changes RM ('000)	Changes %
Revenue	21,901	20,063	1,838	9%
Profit before tax before gain on disposal of subsidiary	269	520	(251)	-48%
Gain on disposal of subsidiary	-	7,208		
Profit before tax after gain on disposal of subsidiary	269	7,728		

Sales revenue improved by 9% over FY 2022 second quarter.

Profit before tax is RM269 thousand compared to the last year same quarter's profit of RM520 thousand before the gain of on disposal of a subsidiary. Despite the higher revenues, the margins in the current quarter were eroded by surging raw material costs and higher freight charges which has also been afflicting the global economies.

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Reporting Quarter 2Q 2022	Previous Quarter 1Q 2022	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	21,901	18,295	3,606	20%
Profit Before Tax (PBT)	269	910	(641)	-70%

This quarter recorded increase in revenue of RM3.6 million compared to the previous quarter and a lower profit before tax by RM641 thousand. The country attained the National Covid-19 Immunization Programme target and entered endemic phase. This has led to the closure of PPV centers and shift in demand and usage of personal protective equipment ("PPE") range. While sales for these products declined, the demand for operating room related products has increased which resulted in 20% improvement in sales revenue in this quarter. However the elevated cost pressure from surging raw material cost and higher freight charges affected the margin in this quarter.



(Company No : 200301016113 (618533-M))
(Incorporated in Malaysia)
SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

16. COMMENTARY ON CURRENT YEAR PROSPECTS

The Company has achieved higher sales revenue in this quarter but lower profit due to cost pressures. Upward inflationary pressure is anticipated to continue for the rest of the year fueled by high prices of raw materials, supply disruptions and higher logistics cost. This will have an impact on sales and profit margins. There is also expected to be a downward trend in sales revenue in the coming quarter as budgetary cuts affecting our customers is expected to result in lower projected demand. The Company will restrategise to ensure competitiveness and work on new business expansion for future growth of the company.

17. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.

18. TAXATION

The effective tax rate is higher than the statutory rate due to certain expenses being disallowed for tax purposes.

	Individual Quarter Ended		Cumulative Quarter Ended	
	30-Jun-22	30-Jun-21	30-Jun-22	30-Jun-21
	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Income tax credit/(expense)	(96)	-	(468)	1
Deferred tax assets/(liabilities)	-	-	ı	1
Total	(96)	-	(468)	-

19. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

20. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

21. CORPORATE PROPOSALS

(i) <u>Proposed Private Placement and/or Proposed Shares Subscription</u>

The Company had on 8 Dec 2021 made an application to Bursa Malaysia Securities Berhad ("Bursa Malaysia") for a Proposed Share Issuance of up to 20% of the total number of issued shares ("Proposed Share Issuance") and entered into a Subscription Agreement with Macquarie Bank Limited ("Macquarie") granting them the right to subscribe for up to 15 million of new Adventa Shares.

On 10 December 2021, the Company had obtained approval from Bursa Malaysia for the listing of and quotation for 30,557,154 new Adventa Shares ("Placement Shares") representing 20% of the Company's total number of issued shares.

On 31 March 2022, the Subscription Agreement with Macquarie had expired and the Company has not placed out any placement shares to any third-party investor.

On 26 May 2022, the Company had made application to Bursa Malaysia for the extension of time ("EOT") of the Proposed Share Issuance for another 6 months from 9 June 2022 and allow all the Placement Shares to be issued to third-party investor(s) in view of the expiry of the Subscription Agreement with Macquarie. Bursa Malaysia had, vide its letter dated 1 June 2022, resolved to grant an extension of time until 9 December 2022 for Adventa to complete the implementation of the Shares Issuance subject to Adventa procuring shareholders' mandate for the shares Issuance at its 19th Annual General Meeting to be convened on 23rd June 2022.

The shareholders had approved the resolution for the 20% General Mandate at the 19th Annual General Meeting held on 23 June 2022.

(ii) <u>Proposed Employee Share Scheme ("Proposed ESS")</u>

On 28 March 2022, the Company proposed to undertake the establishment of an employee share scheme, which comprises the proposed employee share option scheme ("Proposed ESOS") and the proposed share grant plan ("Proposed SGP"), of up to 15% of the total number of issued shares in the Company (excluding treasury shares of Adventa, if any) at any point in time during the duration of the employee share scheme, for eligible employees and Directors of the Company and its subsidiaries ("Eligible Persons"), which are not dormant, who fulfill the eligibility criteria as set out in the by-laws of the employee share scheme. ("Proposed ESS")

On 22 April 2022, Bursa Malaysia Securities Berhad had granted the approval for the implementation of the Proposed ESS and the scheme and approval from shareholders at the 19th Annual General Meeting ("AGM") held on 23 June 2022 was also granted.

Save for the above, there was no other corporate proposal announced as at the date of this interim report but pending completion.



(Company No : 200301016113 (618533-M))
(Incorporated in Malaysia)
SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

22. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as of financial year ended 31 March 2022 as below.

	As at 30-Jun-22	As at 30-Jun-21
Current (Secured):	RM ('000)	RM ('000)
Trade loan	3,041	170
Total Bank Borrowings	3,041	170

23. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

24. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

a. Basic

	Individual Quarter Ended		Cumulativ End	-
	30-Jun-22	30-Jun-21	30-Jun-22	30-Jun-21
Profit attributable to ordinary equity holders of the parent (RM '000)	82	7,711	782	6,589
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	0.05	5.05	0.51	4.31

b. Diluted

There were no diluted earnings per share.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) SECOND QUARTER REPORT ENDED 30 JUNE 2022

UNAUDITED NOTES TO FINANCIAL STATEMENTS

25. (LOSS) / PROFIT BEFORE TAX

(Loss) / profit before tax is stated after charging/(crediting):

	Individual Quarter Ended		Cumulative Quarter Ended	
	30-Jun-22 30-Jun-21		30-Jun-22	30-Jun-21
	RM'000	RM'000	RM'000	RM'000
Other income	40	(48)	89	46
Interest income	75	28	144	37
Gain On Disposal of Investment	-	7,208	-	7,208
Net foreign exchange loss/(gain)	(21)	14	(129)	(81)
Interest expenses	(367)	(277)	(701)	(630)

26. REALISED AND UNREALISED PROFITS/(LOSSES)

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is as follows:

	As at 30-Jun-2022	As at 30-Jun-2021
Group's total (Accumulated losses)/Retained profits:	RM'000	RM'000
Realised	17,120	(40,488)
Unrealised	(3,982)	(6,393)
Total Realised and unrealised	13,138	(46,881)
Less: Consol adjustments	(1,757)	50,943
(Accumulated losses) / Retained profits	11,381	4,062

27. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 29th Aug 2022.

By Order of the Board Adventa Berhad CHUA SIEW CHUAN Company Secretary MAICSA 0777689